Home/Pipeline/Morphomer Tau aggregation inhibitor (e.g., ACI-3024)

Morphomer Tau aggregation inhibitor (e.g., ACI-3024)

Alzheimer's Disease

Phase 1Partnered with Lilly

Key Facts

Indication

Alzheimer's Disease

Phase

Phase 1

Status

Partnered with Lilly

Company

AC Immune

About AC Immune

AC Immune's mission is to diagnose, treat, and prevent neurodegenerative diseases through a precision medicine approach. The company has achieved significant validation through high-value partnerships with major pharmaceutical firms like Takeda, Janssen, and Lilly, and its pipeline features promising Phase 2 candidates in Alzheimer's and Parkinson's disease. Its strategy balances internal R&D of first- and best-in-class candidates with strategic collaborations that provide non-dilutive funding and de-risk development.

View full company profile

Therapeutic Areas

Alzheimer's Disease Parkinson's Disease Neurodegenerative Diseases

Other Alzheimer's Disease Drugs

Drug	Company	Phase	Status
ALZN002	Alzamend Neuro	Preclinical	Research
P021	Phanes Biotech	Preclinical	Active
PB43D	Phanes Biotech	Preclinical	Active
UB-311	Vaxxinity	Phase 2	Active
Lecanemab	BioArctic	Launched	Active (Commercial)
BAN2401	BioArctic	Preclinical	Active
itMSCs	Stemedica Cell Technologies	Clinical Development	Active
Aucuba-001	Aucuba Sciences	Preclinical	Active
ALTA Drug Series	Alteron Therapeutics	Preclinical	Research
NTRX-07	NeuroTherapia	Phase 2	Active
3D Neuronal Disease Models	BioTalentum	Research	Active
Not Publicly Disclosed	Cerecin	Phase 1/2	Active